Barely Significant
← all excerpts

Ixazomib for Desensitization (IXADES) in Highly Sensitized Kidney Transplant Candidates: A Phase II Clinical Trial.

Kidney360 · 2023 · PMC10371382 · PMID 36951387

Europe PMCDOI
1
hedged sentence
0.0080
closest p · 0.2× alpha
0.0080
boldest claim

The sentences

did not reach statistical significanceP = 0.008actually significant
Although the decline in total B cells (CD3 − CD19 + CD20 + ) and naïve B cells (CD3 − CD19 + CD20 + CD27 − CD38 lo ) did not reach statistical significance, mature/activated B cells (CD3 − CD19 + CD20 + CD27 + CD38 moderate ) declined significantly from 313 (267–392) cells/10 5 lymphocytes to 64 (28–166), P = 0.008, and memory B cells (CD3 − CD19 + CD20 + CD27 + CD38 − ) decreased from 608 (380–842) cells/10 5 lymphocytes to 101 (36–200), P = 0.004 (Figure 4 ).

also in 12,641 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.